Dr. Mohammed Rassool

Mohammed Rassool is a clinical researcher specializing in tuberculosis and HIV therapeutics, with strong involvement in major international trials evaluating novel and shortened treatment regimens. His work is closely aligned with global consortia such as STREAM, TB-PRACTECAL, and PanACEA, contributing to evidence that informs WHO guidelines. He collaborates across Africa and other high-burden regions, focusing on pragmatic, program-relevant research.

His publications highlight expertise in rifampicin-resistant and multidrug-resistant tuberculosis, including evaluation of bedaquiline-based and pretomanid-containing regimens, as well as emerging agents such as BTZ-043. He has contributed to pivotal trials demonstrating the safety, efficacy, and durability of all-oral, shorter regimens, alongside pharmacokinetic, safety, and microbiome analyses that refine risk stratification and individualized care.

Rassool’s research also addresses TB-HIV co-infection and metabolic comorbidities, examining antiretroviral optimization during TB therapy and treatment outcomes in people with diabetes. His portfolio reflects strengths in clinical trial methodology, translational pharmacology, and health economic evaluation, advancing safer, shorter, and more cost-effective therapies for populations disproportionately affected by TB and HIV.